On April 25, 2025, Shanghai Escugen Biotechnology Co., Ltd. and ConjugateBio Inc., based in the United States, jointly announced the signing of an exclusive option agreement for the EZWi-Fit® platform technology.

Under the exclusive option agreement, ConjugateBio, upon payment of an option fee to Escugen Biotech, has obtained the exclusive option right to use the EZWi-Fit® platform technology to develop ADC products targeting specified targets, as well as the corresponding global exclusive license upon the exercise of the option. According to the licensing agreement, Escugen Biotech is eligible to receive over $100 million in development, regulatory, and commercialization milestone payments, in addition to tiered royalties based on global annual net sales.

This collaboration marks another international potential licensing opportunity for Escugen’s next-generation ADC platform technology EZWi-Fit®, further solidifying the platform’s recognition by multiple international peers and expanding the global influence of both Escugen Biotech and the EZWi-Fit® platform technology.

About ConjugateBio Inc.

ConjugateBio is a privately held, venture-backed biotechnology company founded in 2022 and headquartered in Princeton, NJ. Currently in stealth mode, the company is advancing a pipeline of first-in-class antibody-drug conjugates (ADCs) designed to target solid tumors with high unmet medical needs. By combining in-licensing and in-house innovation across antibodies and proprietary linker-payload technologies, ConjugateBio is building a robust portfolio aimed at treating a wide range of cancers—from ultra-rare conditions to some of the most common malignancies.

About Escugen Biotechnology

Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC drugs. Currently, Escugen's lead Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC pipeline targeting new or validated targets. Escugen has also successfully licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.